Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
NCT06179888
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key points about the study:
- The treatment involves a unique combination of therapies that target the cancer cells more effectively.
- Patients will receive personalized treatment plans based on their individual health needs and cancer characteristics.
- The study aims to assess how well this combination therapy works compared to standard treatments.
- Researchers are also looking at the side effects and overall quality of life for patients undergoing this new treatment.
- This study is notable for its focus on tailoring treatments to each patient, which could lead to better results and fewer side effects.
Third Opinion AI Generated Synopsis
Trial Summary
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
Name: Lisa X. Lee
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 310-423-8965
Email:
Phone: 310-423-8965
Name: David Oveisi
Email:
Phone:
Email:
Phone:
Name: Richard L. Deming
Email:
Phone:
Email:
Phone:
Name: Sarah A. Holstein
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 402-559-5600
Email:
Phone: 402-559-5600
Name: Sarah A. Holstein
Email:
Phone:
Email:
Phone:
Name: Sarah A. Holstein
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 212-639-7592
Email:
Phone: 212-639-7592
Name: Hamza Hashmi
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 212-639-7592
Email:
Phone: 212-639-7592
Name: Hamza Hashmi
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 212-639-7592
Email:
Phone: 212-639-7592
Name: Hamza Hashmi
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 212-639-7592
Email:
Phone: 212-639-7592
Name: Hamza Hashmi
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 212-639-7592
Email:
Phone: 212-639-7592
Name: Hamza Hashmi
Email:
Phone:
Email:
Phone:
Name: Alison K. Conlin
Email:
Phone:
Email:
Phone:
Name: Alison K. Conlin
Email:
Phone:
Email:
Phone:
Name: Alison K. Conlin
Email:
Phone:
Email:
Phone:
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 832-522-2873
Email:
Phone: 832-522-2873
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 281-242-2873
Email:
Phone: 281-242-2873
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 713-790-2700
Email:
Phone: 713-790-2700
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 515-241-3305
Email:
Phone: 515-241-3305
Name: Seema Harichand-Herdt
Email:
Phone:
Email:
Phone:
Name: Alison K. Conlin
Email:
Phone:
Email:
Phone:
Name: Alison K. Conlin
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 515-241-3305
Email:
Phone: 515-241-3305
Name: Seema Harichand-Herdt
Email:
Phone:
Email:
Phone:
Name: Brion V. Randolph
Email:
Phone:
Email:
Phone:
Name: Mark A. Schroeder
Email:
Phone:
Email:
Phone:
Name: Mark A. Schroeder
Email:
Phone:
Email:
Phone:
Name: Mark A. Schroeder
Email:
Phone:
Email:
Phone:
Name: Mark A. Schroeder
Email:
Phone:
Email:
Phone:
Name: Mark A. Schroeder
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 864-241-6251
Email:
Phone: 864-241-6251
Name: Suzanne R. Fanning
Email:
Phone:
Email:
Phone:
Name: Brion V. Randolph
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Sascha A. Tuchman
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Sami Ibrahimi
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 916-734-3089
Email:
Phone: 916-734-3089
Name: Aaron Rosenberg
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 515-241-3305
Email:
Phone: 515-241-3305
Name: Seema Harichand-Herdt
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 515-241-6727
Email:
Phone: 515-241-6727
Name: Seema Harichand-Herdt
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 515-241-3305
Email:
Phone: 515-241-3305
Name: Seema Harichand-Herdt
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 515-241-3305
Email:
Phone: 515-241-3305
Name: Seema Harichand-Herdt
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 515-241-3305
Email:
Phone: 515-241-3305
Name: Seema Harichand-Herdt
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 515-241-3305
Email:
Phone: 515-241-3305
Name: Seema Harichand-Herdt
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 515-241-3305
Email:
Phone: 515-241-3305
Name: Seema Harichand-Herdt
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 312-355-3046
Email:
Phone: 312-355-3046
Name: Ana Maria Avila Rodriguez
Email:
Phone:
Email:
Phone:
